The local control rate, disease-free survival (DFS), and overall survival (OS) of the cohort (Fig. 2A: local control rate, Fig. 2B: DFS, Fig. 2C: OS).

<p>The local control rate, disease-free survival (DFS), and overall survival (OS) of the cohort (Fig. 2A: local control rate, Fig. 2B: DFS, Fig. 2C: OS).</p

Univariate analyses of overall survival, local control, and disease-free survival.

<p>Univariate analyses of overall survival, local control, and disease-free survival.</p

Cumulative incidence of Grade 3+ acute complications to NCI CTC 3.0 (during ACT and CRT).

<p>Cumulative incidence of Grade 3+ acute complications to NCI CTC 3.0 (during ACT and CRT).</p

Patient characteristics.

*<p>: CRT: concurrent chemoradiotherapy;</p>†<p>: ACT: adjuvant chemotherapy;</p><p>LN: lymph nodes;</p>††<p>: American Joint Committee on Cancer;</p>§<p>: R0: no residual tumor after resection;</p>∥<p>:R1: microscopic residual tumor after resection;</p>¶<p>:D2: removal of all invaded N2 lymph nodes:</p>#<p>:D1:removal of all invaded N1 lymph nodes;</p><p>CCT: concurrent chemotherapy.</p

Monthly distribution of non-EV71 and non-CVA16 enterovirus serotypes during 2009 to June 2013 in Jinan, China.

<p>Monthly distribution of non-EV71 and non-CVA16 enterovirus serotypes during 2009 to June 2013 in Jinan, China.</p

The enterovirus serotypes identified in hand-foot-mouth disease during 2009 to June 2013, in Jinan, China.

<p>The enterovirus serotypes identified in hand-foot-mouth disease during 2009 to June 2013, in Jinan, China.</p

Monthly distribution of CVA6 associated with HFMD during 2009 to June 2013 in Jinan, China.

<p>Monthly distribution of CVA6 associated with HFMD during 2009 to June 2013 in Jinan, China.</p

Monthly distribution of CVA10 associated with HFMD during 2009 to June 2013 in Jinan, China.

<p>Monthly distribution of CVA10 associated with HFMD during 2009 to June 2013 in Jinan, China.</p

Phylogenetic analysis based on the 5’-UTR region of HFMD cases during 2009 to June 2013 in Jinan, China.

<p>A total of 29 representative sequences (representing 12 serotypes) from this study and 12 reference strains worldwide were used to build the tree. Jinan sequences were labeled by black solid dot. Abbreviations: JN, Jinan; CHN, China.</p

Comparison of age distribution among four age groups based on percentage of patients’ number.

<p>A) Comparison between urban and suburb/rural patients. B) Comparison between VSARI and SARI patients.</p